Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196

Watchlist Manager
Shanghai Fosun Pharmaceutical Group Co Ltd Logo
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Watchlist
Price: 26.24 CNY -3.78% Market Closed
Market Cap: 67.1B CNY
Have any thoughts about
Shanghai Fosun Pharmaceutical Group Co Ltd?
Write Note

Operating Margin
Shanghai Fosun Pharmaceutical Group Co Ltd

3.9%
Current
6%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.9%
=
Operating Profit
1.6B
/
Revenue
40.5B

Operating Margin Across Competitors

Country CN
Market Cap 70.1B CNY
Operating Margin
4%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Shanghai Fosun Pharmaceutical Group Co Ltd
Glance View

Market Cap
70.1B CNY
Industry
Pharmaceuticals

Shanghai Fosun Pharmaceutical Group Co., Ltd. is a leading player in the global healthcare landscape, anchored in its commitment to innovation and quality. Founded in 1994 and based in Shanghai, China, the company operates through a diverse portfolio that includes pharmaceuticals, biotechnology, medical devices, and healthcare services. With a strategic focus on research and development, Fosun Pharma has developed a strong pipeline of proprietary drugs and vaccines, enhancing its position in both domestic and international markets. Its ability to capitalize on China’s booming healthcare sector, alongside strategic alliances with reputable global firms, positions it as a formidable competitor in the ever-evolving landscape of healthcare. For investors, Fosun Pharma presents an intriguing opportunity, characterized by robust growth potential and strategic expansion initiatives. Over recent years, the company has aggressively pursued both organic growth and acquisitions to strengthen its product offerings and market reach. This includes partnerships with renowned companies to develop cutting-edge treatments and technologies. The organization’s emphasis on global healthcare trends, along with its commitment to enhancing patient well-being through innovative solutions, underscores its long-term vision. Investors can view Fosun Pharma as a vital player in addressing healthcare needs, especially in the wake of increasing global demand for health solutions, thus making it an attractive proposition in the pharmaceutical industry.

Intrinsic Value
38.86 CNY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.9%
=
Operating Profit
1.6B
/
Revenue
40.5B
What is the Operating Margin of Shanghai Fosun Pharmaceutical Group Co Ltd?

Based on Shanghai Fosun Pharmaceutical Group Co Ltd's most recent financial statements, the company has Operating Margin of 3.9%.